Li Ren Kong

9PUBLICATIONS
50CO-AUTHORS
Molecular targetsCancer cell biologyCancer geneticsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 17, 2026
A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas.

|Aug 01, 2025
Charting New Paths in Cancer Research: Insights from the Frontiers in Cancer Science Conference 2024.

Giang Le Minh, Sasidharan Swarnalatha Lucky, Shazib Pervaiz

|Aug 25, 2023
A transcriptional response to replication stress selectively expands a subset of Brca2-mutant mammary epithelial cells.

Maryam Ghaderi Najafabadi, G Kenneth Gray, Li Ren Kong

|Apr 17, 2021
DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death.

Heng Boon Low, Zhen Lim Wong, Bangyuan Wu

|Aug 21, 2020
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma.

Wan Qin Chong, Chwee Ming Lim, Arvind Kumar Sinha

|May 01, 2020
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.

Li Ren Kong, Richard Weijie Ong, Tuan Zea Tan

Pageof 2

Frequent Collaborators

5 joint publications

Tuan Zea Tan

4 joint publications

Boon Cher Goh

3 joint publications

Yaw Chyn Lim

3 joint publications

Sanjay De Mel